Innoviva (INVA) Competitors $17.84 -0.09 (-0.50%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INVA vs. FOLD, LGND, GERN, CLDX, MNKD, DVAX, BCRX, NVAX, MYGN, and OPKShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), Celldex Therapeutics (CLDX), MannKind (MNKD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Myriad Genetics (MYGN), and OPKO Health (OPK). These companies are all part of the "biotechnology" industry. Innoviva vs. Amicus Therapeutics Ligand Pharmaceuticals Geron Celldex Therapeutics MannKind Dynavax Technologies BioCryst Pharmaceuticals Novavax Myriad Genetics OPKO Health Innoviva (NASDAQ:INVA) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability. Does the MarketBeat Community prefer INVA or FOLD? Amicus Therapeutics received 229 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 73.17% of users gave Amicus Therapeutics an outperform vote while only 57.69% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformInnovivaOutperform Votes30057.69% Underperform Votes22042.31% Amicus TherapeuticsOutperform Votes52973.17% Underperform Votes19426.83% Which has more volatility and risk, INVA or FOLD? Innoviva has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Which has stronger earnings & valuation, INVA or FOLD? Innoviva has higher earnings, but lower revenue than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$352.75M3.17$179.72M$0.6925.86Amicus Therapeutics$493.67M5.93-$151.58M-$0.34-28.82 Do institutionals & insiders believe in INVA or FOLD? 99.1% of Innoviva shares are owned by institutional investors. 1.7% of Innoviva shares are owned by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer INVA or FOLD? In the previous week, Amicus Therapeutics had 4 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Amicus Therapeutics and 7 mentions for Innoviva. Innoviva's average media sentiment score of 0.58 beat Amicus Therapeutics' score of 0.42 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amicus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate INVA or FOLD? Amicus Therapeutics has a consensus target price of $16.88, suggesting a potential upside of 72.19%. Given Amicus Therapeutics' higher probable upside, analysts clearly believe Amicus Therapeutics is more favorable than Innoviva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is INVA or FOLD more profitable? Innoviva has a net margin of 18.31% compared to Amicus Therapeutics' net margin of -21.21%. Innoviva's return on equity of 20.84% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Innoviva18.31% 20.84% 11.38% Amicus Therapeutics -21.21%-15.97%-3.17% SummaryInnoviva and Amicus Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Diversified Trading InstituteCombine the QQQ, IWM and SPY in one tradeIf you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…You can find out about this “2-Click Trade” here. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$6.57B$5.01B$9.08BDividend YieldN/A3.09%4.87%4.21%P/E Ratio25.8610.55135.0717.15Price / Sales3.17195.041,120.63116.80Price / Cash5.3157.1640.5837.88Price / Book1.675.104.754.78Net Income$179.72M$151.51M$118.50M$225.60M7 Day Performance-3.98%-2.13%-1.85%-1.21%1 Month Performance-6.40%-3.13%11.28%3.09%1 Year Performance10.06%11.54%29.92%16.48% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva1.9828 of 5 stars$17.84-0.5%N/A+11.7%$1.12B$352.75M25.86112High Trading VolumeFOLDAmicus Therapeutics4.326 of 5 stars$9.89+5.7%$16.88+70.6%-23.7%$2.96B$493.67M-28.71480Analyst DowngradeLGNDLigand Pharmaceuticals4.9831 of 5 stars$123.94+6.0%$147.00+18.6%+65.4%$2.34B$152.42M47.4480Analyst RevisionGERNGeron3.8487 of 5 stars$3.79-1.8%$7.15+88.7%+61.6%$2.29B$29.48M-12.06141Short Interest ↓CLDXCelldex Therapeutics2.6676 of 5 stars$26.37+3.8%$62.25+136.1%-33.5%$1.75B$6.88M-9.89160Analyst ForecastNews CoveragePositive NewsMNKDMannKind3.199 of 5 stars$6.29-3.8%$8.67+37.8%+105.4%$1.73B$198.96M93.43400Analyst UpgradeAnalyst RevisionNews CoverageDVAXDynavax Technologies4.6677 of 5 stars$12.98+0.2%$22.00+69.5%-4.1%$1.71B$260.81M100.00408Positive NewsBCRXBioCryst Pharmaceuticals3.7226 of 5 stars$7.35-2.4%$15.60+112.2%+34.2%$1.52B$412.58M-12.34530Positive NewsNVAXNovavax3.8281 of 5 stars$9.26+1.6%$17.83+92.6%+77.2%$1.48B$847.25M-4.031,543MYGNMyriad Genetics4.4467 of 5 stars$14.19-1.7%$24.27+71.1%-34.3%$1.29B$823.60M-11.102,700OPKOPKO Health4.1722 of 5 stars$1.56-2.2%$2.75+76.8%-1.3%$1.06B$711.41M-8.343,930Analyst UpgradePositive News Related Companies and Tools Related Companies Amicus Therapeutics Alternatives Ligand Pharmaceuticals Alternatives Geron Alternatives Celldex Therapeutics Alternatives MannKind Alternatives Dynavax Technologies Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Myriad Genetics Alternatives OPKO Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INVA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INVA Stock Alerts